Sector News

Mylan in advanced talks for Merck KGaA's $4B-plus OTC unit: report

April 14, 2018
Life sciences

Pfizer may have run into snags trying to sell its consumer health business, but Merck KGaA may be in advanced discussions with a player over its own for-sale unit. And that player is Mylan, according to reports.

The two companies are negotiating a price between $4.3 billion and $4.9 billion, Reuters says, although there’s no certainty they’ll lock down a deal. The German drugmaker has also reportedly chit-chatted with private equity groups about a sale, according to the news service.

Mylan, for its part, denies the report. “Although it’s Mylan’s policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue,” the company said in a statement.

Merck KGaA first said that it was considering a sale last September, pointing to “increasing internal constraints to fund” the consumer health business.

These days, though, there’s less competition for the buy. Companies including Nestlé, which is working to expand further into healthcare, and consumer giant Reckitt Benckiser, have already dropped out of the running.

It’s not the first time Mylan has gone after a deal in the consumer biz. It spent the better part of 2015 in hostile pursuit of store-brand specialist Perrigo, whose shareholders ultimately rejected Mylan’s offer. And in the wake of that offer, it snapped up Sweden’s Meda.

With the U.S. generics sector now in turmoil, diversification for the knockoffs giant has been more important than ever. Bernstein’s Ronny Gal wrote to clients Tuesday that Mylan is in a decent place under the circumstances, noting that the “downside scenario based on U.S. price erosion is moderate” thanks to boosts from Mylan’s growing biosimilar share and outside-the-U.S. products.

It’s also not the first time Mylan and Merck KGaA have talked transaction, Reuters noted. Back in 2007, Mylan took Merck’s generics unit off its hands in a $6.7 billion deal that also sent severe allergy blockbuster EpiPen over to the copycat.

Meanwhile, Pfizer, which boasts a larger OTC business than Merck’s, has been watching its own sale options dwindle as retail kings such as Amazon threaten OTC drugmakers’ sales. Late last month, both Reckitt and GlaxoSmithKline withdrew from the bidding process, though rumor has it there’s a small chance the New York drugmaker could still unload the asset to Procter & Gamble.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 25, 2023

UK regulator makes biggest changes in 20 years to speed up trials, attract global studies

Life sciences

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.

March 25, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

Life sciences

Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.

March 25, 2023

Sanofi’s Dupixent receives EC approval for atopic dermatitis

Life sciences

Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.

How can we help you?

We're easy to reach